MedTrace Logo

Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90

NCT04437420 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2020-06-23

No results posted yet for this study

Summary

NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).

Conditions

  • Acute T Lymphoblastic Leukemia (T-ALL)
  • Acute B Lymphoblastic Leukemia (B-ALL)

Interventions

DRUG

injection of BEP 800

injection of BEP 800

OTHER

Control

no injection of BEP 800

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04437420 on ClinicalTrials.gov